@article{Kumar2025, 
author = {Deepak Kumar and Rishabha Malviya and Shriyansh Srivastava and Sathvik Belagodu Sridhar and Sirajunisa Talath and Javedh Shareef and Bhupendra G. Prajapati},
title = {Personalized immunization against Mpox Clades I and Ib: Strategies to combat the emerging epidemic},
year = {2025},
journal = {Infectious Medicine},
volume = {4},
number = {1},
pages = {100166},
keywords = {Orthopoxvirus, Clade Ib, MVA-BN, LC16-KMB, OrthopoxVac, Global outbreak},
url = {https://www.sciopen.com/article/10.1016/j.imj.2025.100166},
doi = {10.1016/j.imj.2025.100166},
abstract = {Mpox, formerly known as monkeypox, is a zoonotic virus of the Orthopoxvirus genus, with recent outbreaks of Clade I and Ib in Central Africa presenting a considerable global health threat. This study reviews current Mpox immunization approaches, focusing on the MVA-BN, LC16-KMB, and OrthopoxVac vaccines. MVA-BN vaccination has been successful in lowering infection risks, particularly in high-risk individuals and is widely used in the USA. LC16-KMB is recommended by the World Health Organization for prevention in afflicted regions. OrthopoxVac, a newer vaccination authorized in Russia, provides wide protection. Adapting vaccination approaches based on epidemiology in particular areas is critical for minimizing Mpox outbreaks.}
}